WeightCare

What it is

Programs include a same-day telehealth visit, medication if approved, physician messaging and monthly check-ins.

Providers may prescribe compounded semaglutide or tirzepatide from a state-licensed pharmacy partner.

It also sells B12, NAD+, sermorelin, coaching and supplements.

WeightCare sells a 1,000 mg NAD+ vial (30 daily doses) for $249 as a one-time purchase or monthly subscription.

Ordering includes a medical questionnaire and a same-day telehealth visit; if approved, a US compounding pharmacy fills the prescription.

The product page states in capitals that compounded NAD+ is not FDA-approved.

Its wellness and energy line also lists sermorelin ($199/month) and B12 lipotropic injections.

Prescribes: Compounded semaglutide and tirzepatide Compounded NAD+ and sermorelin (not FDA-approved), plus GLP-1 weight-loss drugs.

What it costs

Insurance: Site does not bill insurance; FSA/HSA and Affirm offered

Prices change often. Check joinweightcare.com before you sign up.

Pros and cons

What users say

Common themes in public posts on Reddit, Trustpilot, the Better Business Bureau and app stores, summarised and linked. Individual experiences vary.

• Reviewers describe refund, cancellation and Groupon-promo billing disputes3
• Some report medication arriving warm or delayed after a pharmacy change3
• Positive reviews mention simple sign-up and weight-loss progress3
• Reviewers describe sign-up as simple and report results on the weight-loss program.3
• Complaints cover refund and cancellation disputes (including Groupon promos), warm or delayed shipments after a pharmacy change and unanswered messages; no Trustpilot reviews seen mention NAD+.3

Records we found

Official and court records we found in public sources as of October 15, 2026. This is not a live or complete record; check fda.gov, ftc.gov and court sites for the latest.

1. Feb 2026
   FDA

   FDA sent a warning letter stating that labels naming WeightCare implied it was the compounder, rendering the products misbranded under sections 502(a) and 502(bb) of the FD&C Act.1

2. Feb 2026
   FDA

   FDA warning letter stating labels naming WeightCare implied it was the compounder of its compounded GLP-1 products, rendering them misbranded (not about NAD+).1